Targets › PD-L1
5 programs from 5 companies in 6 trials: 5 Phase 2, 1 Phase 3; Oncology, Gastroenterology; next expected readout Nov 2026.
Open in Phaseline: the race on PD-L1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shandong Cancer Hospital and Institute | Tuvonralimab PD-L1 inhibitor | PD-L1 | Phase 3 | Local Advanced Rectal Cancer; Rectal Malignant Neoplasms | Nov 2026 |
| Jiangxi Provincial Cancer Hospital | TQB2450 PD-L1 inhibitor antibody | PD-L1 | Phase 2 | Esophageal Squamous Cell Carcinoma | Nov 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Cardonilizumab PD-L1 inhibitor | PD-L1 | Phase 2 | Esophageal Cancer | Dec 2026 |
| The First Affiliated Hospital with Nanjing Medical University | Bemosubaiabimab Anti-PD-L1 monoclonal antibody | PD-L1 | Phase 2 | Esophageal Cancer | Apr 2028 |
| First Affiliated Hospital of Zhejiang University | Tuvonralimab PD-L1 inhibitor | PD-L1 | Phase 2 | Locally Advanced Rectal Cancer (LARC) | Dec 2029 |
Esophageal Cancer (2) Local Advanced Rectal Cancer (1) Rectal Malignant Neoplasms (1) Esophageal Squamous Cell Carcinoma (1) Locally Advanced Rectal Cancer (LARC) (1)
small molecule (3), antibody (1)
Shandong Cancer Hospital and Institute (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) Jiangxi Provincial Cancer Hospital (1) The First Affiliated Hospital with Nanjing Medical University (1) First Affiliated Hospital of Zhejiang University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.